Standardisation of information submitted to an endpoint committee for cause of death assignment in a cancer screening trial – lessons learnt from CAP (Cluster randomised triAl of PSA testing for Prostate cancer)
Background In cancer screening trials where the primary outcome is target cancer-specific mortality, the unbiased determination of underlying cause of death (UCD) is crucial. To minimise bias, the UCD should be independently verified by expert reviewers, blinded to death certificate data and trial a...
Uloženo v:
| Vydáno v: | BMC medical research methodology Ročník 15; číslo 1; s. 6 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
London
BioMed Central
23.01.2015
BioMed Central Ltd |
| Témata: | |
| ISSN: | 1471-2288, 1471-2288 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Background
In cancer screening trials where the primary outcome is target cancer-specific mortality, the unbiased determination of underlying cause of death (UCD) is crucial. To minimise bias, the UCD should be independently verified by expert reviewers, blinded to death certificate data and trial arm. We investigated whether standardising the information submitted for UCD assignment in a population-based randomised controlled trial of prostate-specific antigen (PSA) testing for prostate cancer reduced the reviewers’ ability to correctly guess the trial arm.
Methods
Over 550 General Practitioner (GP) practices (>415,000 men aged 50–69 years) were cluster-randomised to PSA testing (intervention arm) or the National Health Service (NHS) prostate cancer risk management programme (control arm) between 2001 and 2007. Assignment of UCD was by independent reviews of researcher-written clinical vignettes that masked trial arm and death certificate information. A period of time after the process began (the initial phase), we analysed whether the reviewers could correctly identify trial arm from the vignettes, and the reasons for their choice. This feedback led to further standardisation of information (second phase), after which we re-assessed the extent of correct identification of trial arm.
Results
1099 assessments of 509 vignettes were completed by January 2014. In the initial phase (n = 510 assessments), reviewers were unsure of trial arm in 33% of intervention and 30% of control arm assessments and were influenced by symptoms at diagnosis, PSA test result and study-specific criteria. In the second phase (n = 589), the respective proportions of uncertainty were 45% and 48%. The percentage of cases whereby reviewers were unable to determine the trial arm was greater following the standardisation of information provided in the vignettes. The chances of a correct guess and an incorrect guess were equalised in each arm, following further standardisation.
Conclusions
It is possible to mask trial arm from cause of death reviewers, by using their feedback to standardise the information submitted to them.
Trial registration
ISRCTN92187251 |
|---|---|
| AbstractList | In cancer screening trials where the primary outcome is target cancer-specific mortality, the unbiased determination of underlying cause of death (UCD) is crucial. To minimise bias, the UCD should be independently verified by expert reviewers, blinded to death certificate data and trial arm. We investigated whether standardising the information submitted for UCD assignment in a population-based randomised controlled trial of prostate-specific antigen (PSA) testing for prostate cancer reduced the reviewers' ability to correctly guess the trial arm. Over 550 General Practitioner (GP) practices (>415,000 men aged 50-69 years) were cluster-randomised to PSA testing (intervention arm) or the National Health Service (NHS) prostate cancer risk management programme (control arm) between 2001 and 2007. Assignment of UCD was by independent reviews of researcher-written clinical vignettes that masked trial arm and death certificate information. A period of time after the process began (the initial phase), we analysed whether the reviewers could correctly identify trial arm from the vignettes, and the reasons for their choice. This feedback led to further standardisation of information (second phase), after which we re-assessed the extent of correct identification of trial arm. 1099 assessments of 509 vignettes were completed by January 2014. In the initial phase (n = 510 assessments), reviewers were unsure of trial arm in 33% of intervention and 30% of control arm assessments and were influenced by symptoms at diagnosis, PSA test result and study-specific criteria. In the second phase (n = 589), the respective proportions of uncertainty were 45% and 48%. The percentage of cases whereby reviewers were unable to determine the trial arm was greater following the standardisation of information provided in the vignettes. The chances of a correct guess and an incorrect guess were equalised in each arm, following further standardisation. It is possible to mask trial arm from cause of death reviewers, by using their feedback to standardise the information submitted to them. Background In cancer screening trials where the primary outcome is target cancer-specific mortality, the unbiased determination of underlying cause of death (UCD) is crucial. To minimise bias, the UCD should be independently verified by expert reviewers, blinded to death certificate data and trial arm. We investigated whether standardising the information submitted for UCD assignment in a population-based randomised controlled trial of prostate-specific antigen (PSA) testing for prostate cancer reduced the reviewers' ability to correctly guess the trial arm. Methods Over 550 General Practitioner (GP) practices (>415,000 men aged 50-69 years) were cluster-randomised to PSA testing (intervention arm) or the National Health Service (NHS) prostate cancer risk management programme (control arm) between 2001 and 2007. Assignment of UCD was by independent reviews of researcher-written clinical vignettes that masked trial arm and death certificate information. A period of time after the process began (the initial phase), we analysed whether the reviewers could correctly identify trial arm from the vignettes, and the reasons for their choice. This feedback led to further standardisation of information (second phase), after which we re-assessed the extent of correct identification of trial arm. Results 1099 assessments of 509 vignettes were completed by January 2014. In the initial phase (n = 510 assessments), reviewers were unsure of trial arm in 33% of intervention and 30% of control arm assessments and were influenced by symptoms at diagnosis, PSA test result and study-specific criteria. In the second phase (n = 589), the respective proportions of uncertainty were 45% and 48%. The percentage of cases whereby reviewers were unable to determine the trial arm was greater following the standardisation of information provided in the vignettes. The chances of a correct guess and an incorrect guess were equalised in each arm, following further standardisation. Conclusions It is possible to mask trial arm from cause of death reviewers, by using their feedback to standardise the information submitted to them. Trial registration ISRCTN92187251 Keywords: Underlying cause of death, Verification, Bias, Prostate cancer, Blinding, Standardisation of information, Trial arm, Endpoint review, Outcome assessors In cancer screening trials where the primary outcome is target cancer-specific mortality, the unbiased determination of underlying cause of death (UCD) is crucial. To minimise bias, the UCD should be independently verified by expert reviewers, blinded to death certificate data and trial arm. We investigated whether standardising the information submitted for UCD assignment in a population-based randomised controlled trial of prostate-specific antigen (PSA) testing for prostate cancer reduced the reviewers' ability to correctly guess the trial arm. Over 550 General Practitioner (GP) practices (>415,000 men aged 50-69 years) were cluster-randomised to PSA testing (intervention arm) or the National Health Service (NHS) prostate cancer risk management programme (control arm) between 2001 and 2007. Assignment of UCD was by independent reviews of researcher-written clinical vignettes that masked trial arm and death certificate information. A period of time after the process began (the initial phase), we analysed whether the reviewers could correctly identify trial arm from the vignettes, and the reasons for their choice. This feedback led to further standardisation of information (second phase), after which we re-assessed the extent of correct identification of trial arm. 1099 assessments of 509 vignettes were completed by January 2014. In the initial phase (n = 510 assessments), reviewers were unsure of trial arm in 33% of intervention and 30% of control arm assessments and were influenced by symptoms at diagnosis, PSA test result and study-specific criteria. In the second phase (n = 589), the respective proportions of uncertainty were 45% and 48%. The percentage of cases whereby reviewers were unable to determine the trial arm was greater following the standardisation of information provided in the vignettes. The chances of a correct guess and an incorrect guess were equalised in each arm, following further standardisation. It is possible to mask trial arm from cause of death reviewers, by using their feedback to standardise the information submitted to them. ISRCTN92187251. Background In cancer screening trials where the primary outcome is target cancer-specific mortality, the unbiased determination of underlying cause of death (UCD) is crucial. To minimise bias, the UCD should be independently verified by expert reviewers, blinded to death certificate data and trial arm. We investigated whether standardising the information submitted for UCD assignment in a population-based randomised controlled trial of prostate-specific antigen (PSA) testing for prostate cancer reduced the reviewers’ ability to correctly guess the trial arm. Methods Over 550 General Practitioner (GP) practices (>415,000 men aged 50–69 years) were cluster-randomised to PSA testing (intervention arm) or the National Health Service (NHS) prostate cancer risk management programme (control arm) between 2001 and 2007. Assignment of UCD was by independent reviews of researcher-written clinical vignettes that masked trial arm and death certificate information. A period of time after the process began (the initial phase), we analysed whether the reviewers could correctly identify trial arm from the vignettes, and the reasons for their choice. This feedback led to further standardisation of information (second phase), after which we re-assessed the extent of correct identification of trial arm. Results 1099 assessments of 509 vignettes were completed by January 2014. In the initial phase (n = 510 assessments), reviewers were unsure of trial arm in 33% of intervention and 30% of control arm assessments and were influenced by symptoms at diagnosis, PSA test result and study-specific criteria. In the second phase (n = 589), the respective proportions of uncertainty were 45% and 48%. The percentage of cases whereby reviewers were unable to determine the trial arm was greater following the standardisation of information provided in the vignettes. The chances of a correct guess and an incorrect guess were equalised in each arm, following further standardisation. Conclusions It is possible to mask trial arm from cause of death reviewers, by using their feedback to standardise the information submitted to them. Trial registration ISRCTN92187251 In cancer screening trials where the primary outcome is target cancer-specific mortality, the unbiased determination of underlying cause of death (UCD) is crucial. To minimise bias, the UCD should be independently verified by expert reviewers, blinded to death certificate data and trial arm. We investigated whether standardising the information submitted for UCD assignment in a population-based randomised controlled trial of prostate-specific antigen (PSA) testing for prostate cancer reduced the reviewers' ability to correctly guess the trial arm.BACKGROUNDIn cancer screening trials where the primary outcome is target cancer-specific mortality, the unbiased determination of underlying cause of death (UCD) is crucial. To minimise bias, the UCD should be independently verified by expert reviewers, blinded to death certificate data and trial arm. We investigated whether standardising the information submitted for UCD assignment in a population-based randomised controlled trial of prostate-specific antigen (PSA) testing for prostate cancer reduced the reviewers' ability to correctly guess the trial arm.Over 550 General Practitioner (GP) practices (>415,000 men aged 50-69 years) were cluster-randomised to PSA testing (intervention arm) or the National Health Service (NHS) prostate cancer risk management programme (control arm) between 2001 and 2007. Assignment of UCD was by independent reviews of researcher-written clinical vignettes that masked trial arm and death certificate information. A period of time after the process began (the initial phase), we analysed whether the reviewers could correctly identify trial arm from the vignettes, and the reasons for their choice. This feedback led to further standardisation of information (second phase), after which we re-assessed the extent of correct identification of trial arm.METHODSOver 550 General Practitioner (GP) practices (>415,000 men aged 50-69 years) were cluster-randomised to PSA testing (intervention arm) or the National Health Service (NHS) prostate cancer risk management programme (control arm) between 2001 and 2007. Assignment of UCD was by independent reviews of researcher-written clinical vignettes that masked trial arm and death certificate information. A period of time after the process began (the initial phase), we analysed whether the reviewers could correctly identify trial arm from the vignettes, and the reasons for their choice. This feedback led to further standardisation of information (second phase), after which we re-assessed the extent of correct identification of trial arm.1099 assessments of 509 vignettes were completed by January 2014. In the initial phase (n = 510 assessments), reviewers were unsure of trial arm in 33% of intervention and 30% of control arm assessments and were influenced by symptoms at diagnosis, PSA test result and study-specific criteria. In the second phase (n = 589), the respective proportions of uncertainty were 45% and 48%. The percentage of cases whereby reviewers were unable to determine the trial arm was greater following the standardisation of information provided in the vignettes. The chances of a correct guess and an incorrect guess were equalised in each arm, following further standardisation.RESULTS1099 assessments of 509 vignettes were completed by January 2014. In the initial phase (n = 510 assessments), reviewers were unsure of trial arm in 33% of intervention and 30% of control arm assessments and were influenced by symptoms at diagnosis, PSA test result and study-specific criteria. In the second phase (n = 589), the respective proportions of uncertainty were 45% and 48%. The percentage of cases whereby reviewers were unable to determine the trial arm was greater following the standardisation of information provided in the vignettes. The chances of a correct guess and an incorrect guess were equalised in each arm, following further standardisation.It is possible to mask trial arm from cause of death reviewers, by using their feedback to standardise the information submitted to them.CONCLUSIONSIt is possible to mask trial arm from cause of death reviewers, by using their feedback to standardise the information submitted to them.ISRCTN92187251.TRIAL REGISTRATIONISRCTN92187251. |
| ArticleNumber | 6 |
| Audience | Academic |
| Author | Martin, Richard M Williams, Naomi J Evans, Simon Hughes, Laura J Donovan, Jenny L Hamdy, Freddie C Hill, Elizabeth M Metcalfe, Chris Davies, Charlotte F Turner, Emma L Ng, Siaw Yein Neal, David E |
| Author_xml | – sequence: 1 givenname: Naomi J surname: Williams fullname: Williams, Naomi J email: naomi.williams@sth.nhs.uk organization: School of Social and Community Medicine, University of Bristol, based at Royal Hallamshire Hospital – sequence: 2 givenname: Elizabeth M surname: Hill fullname: Hill, Elizabeth M email: liz.hill@bristol.ac.uk organization: School of Social and Community Medicine, University of Bristol – sequence: 3 givenname: Siaw Yein surname: Ng fullname: Ng, Siaw Yein email: siawyein.Ng@nuth.nhs.uk organization: School of Social and Community Medicine, University of Bristol, based at Freeman Hospital – sequence: 4 givenname: Richard M surname: Martin fullname: Martin, Richard M organization: School of Social and Community Medicine, University of Bristol – sequence: 5 givenname: Chris surname: Metcalfe fullname: Metcalfe, Chris organization: School of Social and Community Medicine, University of Bristol – sequence: 6 givenname: Jenny L surname: Donovan fullname: Donovan, Jenny L organization: School of Social and Community Medicine, University of Bristol – sequence: 7 givenname: Simon surname: Evans fullname: Evans, Simon organization: Royal United Hospital – sequence: 8 givenname: Laura J surname: Hughes fullname: Hughes, Laura J organization: Department of Oncology, University of Cambridge, Addenbrooke’s Hospital – sequence: 9 givenname: Charlotte F surname: Davies fullname: Davies, Charlotte F organization: School of Social and Community Medicine, University of Bristol – sequence: 10 givenname: Freddie C surname: Hamdy fullname: Hamdy, Freddie C organization: Nuffield Department of Surgical Sciences, University of Oxford, John Radcliffe Hospital – sequence: 11 givenname: David E surname: Neal fullname: Neal, David E organization: Department of Oncology, University of Cambridge, Addenbrooke’s Hospital – sequence: 12 givenname: Emma L surname: Turner fullname: Turner, Emma L organization: School of Social and Community Medicine, University of Bristol |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25613468$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1ks1q3DAQx01JaT7aa49F0Et6cGLJlu29FJalXxDoQtqz0EqjjYItbSU50Fvfoc_WF-iTdJTdLBto8EGW5vf_z4w0p8WR8w6K4jWtLijt20vadLRkrO9Lysv2WXGyPzg6-D8uTmO8rSra9XX7ojhmvKV10_YnxZ_rJJ2WQdsok_WOeEOsMz6M222cVqNNCTRJnkhHwOmNty4R5cf7ABCEiZJThKzVINMNkTHatRsBOeuIxLBTEEhUAcBZtyYpWDmQv79-kwFi9C7iKgPiJviRLOZLcr4YpphQFLA-P9qYSwh2PuQsy-s5SRBTtsrpl8HHJBPsEr17WTw3cojwareeFd8_fvi2-Fxeff30ZTG_KhWveSpXnWKzSgHUlWa97qqZYSteNbJrKVDDeqWbmiltuJQ1b1dUqhVjBmOMG06hPiveb303eE2gFTYc5CA2wY4y_BReWvE44uyNWPs70TRs1jOOBuc7g-B_TNiRwE4VDIN04KcoaNtjrhltM_p2i67lACK_ETqqjIs5b2jdzSrWInXxHwo_DaNVODvG4vkjwZvDFva1P4wIAs0WUHjJMYARyqb74UBnOwhaiTyJIg-byMMmKBcHhexlD85PCi63goigW0MQt34KDp_vKcU_tiry7A |
| CitedBy_id | crossref_primary_10_1038_bjc_2016_378 crossref_primary_10_1056_NEJMoa1606220 crossref_primary_10_1038_bjc_2016_162 crossref_primary_10_1186_s13063_020_04968_x crossref_primary_10_1007_s40273_015_0326_3 crossref_primary_10_1016_j_canep_2016_08_022 crossref_primary_10_1056_NEJMoa2214122 crossref_primary_10_1001_jama_2024_4011 |
| Cites_doi | 10.1016/j.cct.2011.07.003 10.1093/ije/dym020 10.1016/S0140-6736(10)60413-8 10.1016/S0022-5347(05)67915-3 10.1038/bjc.2014.242 10.1016/S0197-2456(00)00095-7 10.1093/jnci/94.3.167 10.1016/j.ejca.2010.09.026 10.1016/S1470-2045(10)70146-7 10.1016/S0140-6736(03)12890-5 10.1177/1740774509356461 10.1016/j.jclinepi.2005.04.006 10.1016/j.lungcan.2012.04.018 10.1016/j.ejca.2010.09.016 10.1111/j.1465-5101.2003.04402.x 10.1258/jrsm.96.9.425 10.1002/ijc.23126 10.1136/jms.7.2.97 10.1093/jnci/92.8.613 10.1177/1740774513498008 10.1177/0962280214523192 |
| ContentType | Journal Article |
| Contributor | Bahl, Amit Koupparis, Anthony Adolfsson, Jan Robinson, Mary Gunnell, David Oxley, Jon Baum, Michael McFarlane, Jon Albertsen, Peter Reid, Colette Zietman, Anthony |
| Contributor_xml | – sequence: 1 givenname: Peter surname: Albertsen fullname: Albertsen, Peter – sequence: 2 givenname: Jan surname: Adolfsson fullname: Adolfsson, Jan – sequence: 3 givenname: Amit surname: Bahl fullname: Bahl, Amit – sequence: 4 givenname: Michael surname: Baum fullname: Baum, Michael – sequence: 5 givenname: David surname: Gunnell fullname: Gunnell, David – sequence: 6 givenname: Anthony surname: Koupparis fullname: Koupparis, Anthony – sequence: 7 givenname: Jon surname: McFarlane fullname: McFarlane, Jon – sequence: 8 givenname: Jon surname: Oxley fullname: Oxley, Jon – sequence: 9 givenname: Colette surname: Reid fullname: Reid, Colette – sequence: 10 givenname: Mary surname: Robinson fullname: Robinson, Mary – sequence: 11 givenname: Anthony surname: Zietman fullname: Zietman, Anthony |
| Copyright | Williams et al.; licensee BioMed Central. 2015 COPYRIGHT 2015 BioMed Central Ltd. |
| Copyright_xml | – notice: Williams et al.; licensee BioMed Central. 2015 – notice: COPYRIGHT 2015 BioMed Central Ltd. |
| CorporateAuthor | CAP Cause of Death Committee |
| CorporateAuthor_xml | – name: CAP Cause of Death Committee |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| DOI | 10.1186/1471-2288-15-6 |
| DatabaseName | Springer Nature OA Free Journals (WRLC) CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1471-2288 |
| ExternalDocumentID | PMC4429825 A541379026 25613468 10_1186_1471_2288_15_6 |
| Genre | Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | United Kingdom |
| GeographicLocations_xml | – name: United Kingdom |
| GrantInformation_xml | – fundername: Cancer Research UK grantid: C18281/A11326 – fundername: Cancer Research UK grantid: C18281/A15064 – fundername: Medical Research Council grantid: MR/K025643/1 – fundername: Cancer Research UK grantid: C18281/A8145 – fundername: Department of Health grantid: HTA 96/20/99 – fundername: Cancer Research UK grantid: C11043/A4286 – fundername: Medical Research Council grantid: MR/K006525/1 |
| GroupedDBID | --- 0R~ 23N 2WC 4.4 53G 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHSBF AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EJD EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 H13 HMCUK HYE IAO IHR INH INR IPNFZ ITC KQ8 M1P M48 MK0 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RIG RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP W2D WOQ WOW XSB AAYXX AFFHD CITATION ALIPV CGR CUY CVF ECM EIF NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c535t-b7c290cee30d28d709f2b504a761e1f28cd432cdf5aa356b1acb22f1e125f51e3 |
| IEDL.DBID | RSV |
| ISICitedReferencesCount | 10 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000349713200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1471-2288 |
| IngestDate | Tue Nov 04 02:01:25 EST 2025 Thu Sep 04 20:01:27 EDT 2025 Tue Nov 11 10:56:51 EST 2025 Tue Nov 04 18:20:39 EST 2025 Mon Jul 21 05:49:18 EDT 2025 Sat Nov 29 06:38:53 EST 2025 Tue Nov 18 20:21:35 EST 2025 Sat Sep 06 07:35:28 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Trial arm Blinding Endpoint review Bias Standardisation of information Outcome assessors Underlying cause of death Verification Prostate cancer |
| Language | English |
| License | This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c535t-b7c290cee30d28d709f2b504a761e1f28cd432cdf5aa356b1acb22f1e125f51e3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://link.springer.com/10.1186/1471-2288-15-6 |
| PMID | 25613468 |
| PQID | 1681259165 |
| PQPubID | 23479 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_4429825 proquest_miscellaneous_1681259165 gale_infotracmisc_A541379026 gale_infotracacademiconefile_A541379026 pubmed_primary_25613468 crossref_citationtrail_10_1186_1471_2288_15_6 crossref_primary_10_1186_1471_2288_15_6 springer_journals_10_1186_1471_2288_15_6 |
| PublicationCentury | 2000 |
| PublicationDate | 2015-01-23 |
| PublicationDateYYYYMMDD | 2015-01-23 |
| PublicationDate_xml | – month: 01 year: 2015 text: 2015-01-23 day: 23 |
| PublicationDecade | 2010 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | BMC medical research methodology |
| PublicationTitleAbbrev | BMC Med Res Methodol |
| PublicationTitleAlternate | BMC Med Res Methodol |
| PublicationYear | 2015 |
| Publisher | BioMed Central BioMed Central Ltd |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd |
| References | Maudsley, Williams (CR6) 1993; 15 De Koning, Blom, Merkelbach, Raaijmakers, Verhaegen, Van Vliet (CR2) 2003; 92 Albertsen, Walters, Hanley (CR8) 2000; 163 Robinson, Rodrigues, Hardcastle, Chamberlain, Mangham, Moss (CR14) 2000; 7 CR18 Newschaffer, Otani, McDonald, Penberthy (CR9) 2000; 92 Marcus, Gareen, Miller, Rosenbaum, Keating, Aberle (CR15) 2011; 32 Mäkinen, Karhunen, Aro, Lahtela, Määttänen, Auvinen (CR10) 2008; 122 CR11 Maclaughlan, Wells (CR7) 2012 Doria-Rose, Marcus, Miller, Bergstralh, Mandel, Tockman (CR22) 2010; 7 Schulz, Altman, Moher, Fergusson (CR24) 2010; 375 Hugosson, Carlsson, Aus, Bergdahl, Khatami, Lodding (CR13) 2010; 11 Turner, Metcalfe, Donovan, Noble, Sterne, Lane (CR17) 2014; 110 Horeweg, Van Klaveren, Groen, Lammers, Weenink, Nackaerts (CR4) 2012; 77 Boutron, Estellat, Ravaud (CR20) 2005; 58 Hróbjartsson, Forfang, Haahr, Als-Nielsen, Brorson (CR21) 2007; 36 Gøtzsche, Nielsen (CR16) 2009; 4 Barry, Andriole, Culkin, Fox, Jones, Carlyle (CR23) 2013; 10 Otto, van Leeuwen, Hoekstra, Merckelbach, Blom, Schröder (CR3) 2010; 46 Lane, Hamdy, Martin, Turner, Neal, Donovan (CR19) 2010; 46 Karch, Rutherford (CR5) 2003; 96 Miller, Yurgalevitch, Weissfeld (CR1) 2000; 21 Black, Haggstrom, Gilbert Welch (CR12) 2002; 94 Frankel, Smith, Donovan, Neal (CR25) 2003; 361 VP Doria-Rose (1176_CR22) 2010; 7 PM Marcus (1176_CR15) 2011; 32 WC Black (1176_CR12) 2002; 94 CJ Newschaffer (1176_CR9) 2000; 92 E Turner (1176_CR17) 2014; 110 J Lane (1176_CR19) 2010; 46 PC Albertsen (1176_CR8) 2000; 163 HJ De Koning (1176_CR2) 2003; 92 KF Schulz (1176_CR24) 2010; 375 S Frankel (1176_CR25) 2003; 361 J Maclaughlan (1176_CR7) 2012 MJ Barry (1176_CR23) 2013; 10 G Maudsley (1176_CR6) 1993; 15 1176_CR11 MH Robinson (1176_CR14) 2000; 7 J Hugosson (1176_CR13) 2010; 11 A Hróbjartsson (1176_CR21) 2007; 36 AB Miller (1176_CR1) 2000; 21 SB Karch (1176_CR5) 2003; 96 PC Gøtzsche (1176_CR16) 2009; 4 T Mäkinen (1176_CR10) 2008; 122 I Boutron (1176_CR20) 2005; 58 N Horeweg (1176_CR4) 2012; 77 S Otto (1176_CR3) 2010; 46 1176_CR18 |
| References_xml | – volume: 32 start-page: 834 issue: 6 year: 2011 end-page: 840 ident: CR15 article-title: The national lung screening Trial's endpoint verification process: determining the cause of death publication-title: Contemp Clin Trials doi: 10.1016/j.cct.2011.07.003 – volume: 36 start-page: 654 issue: 3 year: 2007 end-page: 663 ident: CR21 article-title: Blinded trials taken to the test: an analysis of randomized clinical trials that report tests for the success of blinding publication-title: Int J Epidemiol doi: 10.1093/ije/dym020 – ident: CR18 – volume: 375 start-page: 1144 issue: 9721 year: 2010 end-page: 1146 ident: CR24 article-title: CONSORT 2010 changes and testing blindness in RCTs publication-title: Lancet doi: 10.1016/S0140-6736(10)60413-8 – volume: 163 start-page: 519 issue: 2 year: 2000 end-page: 523 ident: CR8 article-title: A comparison of cause of death determination in men previously diagnosed with prostate cancer who died in 1985 or 1995 publication-title: J Urol doi: 10.1016/S0022-5347(05)67915-3 – volume: 110 start-page: 2829 issue: 12 year: 2014 end-page: 2836 ident: CR17 article-title: Design and preliminary recruitment results of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP) publication-title: Br J Cancer doi: 10.1038/bjc.2014.242 – volume: 21 start-page: 400S issue: 6 year: 2000 end-page: 406S ident: CR1 article-title: Death review process in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial publication-title: Control Clin Trials doi: 10.1016/S0197-2456(00)00095-7 – volume: 4 start-page: 1 year: 2009 ident: CR16 article-title: Screening for breast cancer with mammography publication-title: Cochrane Database Syst Rev – volume: 94 start-page: 167 issue: 3 year: 2002 end-page: 173 ident: CR12 article-title: All-cause mortality in randomized trials of cancer screening publication-title: J Natl Cancer Inst doi: 10.1093/jnci/94.3.167 – volume: 46 start-page: 3061 issue: 17 year: 2010 end-page: 3067 ident: CR3 article-title: Blinded and uniform causes of death verification in cancer screening: A major influence on the outcome of a prostate cancer screening trial? publication-title: Eur J Cancer doi: 10.1016/j.ejca.2010.09.026 – volume: 15 start-page: 192 issue: 2 year: 1993 end-page: 201 ident: CR6 article-title: Death certification by house officers and general practitioners—practice and performance publication-title: J Public Health – volume: 11 start-page: 725 issue: 8 year: 2010 end-page: 732 ident: CR13 article-title: Mortality results from the Göteborg randomised population-based prostate-cancer screening trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(10)70146-7 – volume: 361 start-page: 1122 issue: 9363 year: 2003 end-page: 1128 ident: CR25 article-title: Screening for prostate cancer publication-title: Lancet doi: 10.1016/S0140-6736(03)12890-5 – volume: 7 start-page: 69 issue: 1 year: 2010 end-page: 77 ident: CR22 article-title: Does the source of death information affect cancer screening efficacy results? A study of the use of mortality review versus death certificates in four randomized trials publication-title: Clin Trials doi: 10.1177/1740774509356461 – year: 2012 ident: CR7 article-title: Death certification reform: a case study on the potential impact on mortality statistics, England and Wales publication-title: Off National Statistics Statistical Bull – ident: CR11 – volume: 58 start-page: 1220 issue: 12 year: 2005 end-page: 1226 ident: CR20 article-title: A review of blinding in randomized controlled trials found results inconsistent and questionable publication-title: J Clin Epidemiol doi: 10.1016/j.jclinepi.2005.04.006 – volume: 77 start-page: 522 issue: 3 year: 2012 end-page: 525 ident: CR4 article-title: Blinded and uniform cause of death verification in a lung cancer CT screening trial publication-title: Lung Cancer doi: 10.1016/j.lungcan.2012.04.018 – volume: 46 start-page: 3095 issue: 17 year: 2010 end-page: 3101 ident: CR19 article-title: Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies publication-title: Eur J Cancer doi: 10.1016/j.ejca.2010.09.016 – volume: 92 start-page: 71 year: 2003 end-page: 78 ident: CR2 article-title: Determining the cause of death in randomized screening trial(s) for prostate cancer publication-title: BJU Int doi: 10.1111/j.1465-5101.2003.04402.x – volume: 96 start-page: 425 issue: 9 year: 2003 end-page: 427 ident: CR5 article-title: Death certification in the UK publication-title: JRSM doi: 10.1258/jrsm.96.9.425 – volume: 122 start-page: 413 issue: 2 year: 2008 end-page: 417 ident: CR10 article-title: Assessment of causes of death in a prostate cancer screening trial publication-title: Int J Cancer doi: 10.1002/ijc.23126 – volume: 7 start-page: 97 issue: 2 year: 2000 end-page: 98 ident: CR14 article-title: Faecal occult blood screening for colorectal cancer at Nottingham: details of the verification process publication-title: J Med Screen doi: 10.1136/jms.7.2.97 – volume: 92 start-page: 613 issue: 8 year: 2000 end-page: 621 ident: CR9 article-title: Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort publication-title: J Natl Cancer Inst doi: 10.1093/jnci/92.8.613 – volume: 10 start-page: 907 issue: 6 year: 2013 end-page: 914 ident: CR23 article-title: Ascertaining cause of death among men in the prostate cancer intervention versus observation trial publication-title: Clin Trials doi: 10.1177/1740774513498008 – volume: 7 start-page: 97 issue: 2 year: 2000 ident: 1176_CR14 publication-title: J Med Screen doi: 10.1136/jms.7.2.97 – volume: 94 start-page: 167 issue: 3 year: 2002 ident: 1176_CR12 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/94.3.167 – volume: 21 start-page: 400S issue: 6 year: 2000 ident: 1176_CR1 publication-title: Control Clin Trials doi: 10.1016/S0197-2456(00)00095-7 – volume: 92 start-page: 613 issue: 8 year: 2000 ident: 1176_CR9 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/92.8.613 – volume: 7 start-page: 69 issue: 1 year: 2010 ident: 1176_CR22 publication-title: Clin Trials doi: 10.1177/1740774509356461 – ident: 1176_CR18 – volume: 361 start-page: 1122 issue: 9363 year: 2003 ident: 1176_CR25 publication-title: Lancet doi: 10.1016/S0140-6736(03)12890-5 – volume: 46 start-page: 3061 issue: 17 year: 2010 ident: 1176_CR3 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2010.09.026 – volume: 11 start-page: 725 issue: 8 year: 2010 ident: 1176_CR13 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(10)70146-7 – volume: 15 start-page: 192 issue: 2 year: 1993 ident: 1176_CR6 publication-title: J Public Health – ident: 1176_CR11 doi: 10.1177/0962280214523192 – volume: 32 start-page: 834 issue: 6 year: 2011 ident: 1176_CR15 publication-title: Contemp Clin Trials doi: 10.1016/j.cct.2011.07.003 – volume: 96 start-page: 425 issue: 9 year: 2003 ident: 1176_CR5 publication-title: JRSM doi: 10.1258/jrsm.96.9.425 – volume: 4 start-page: 1 year: 2009 ident: 1176_CR16 publication-title: Cochrane Database Syst Rev – volume: 375 start-page: 1144 issue: 9721 year: 2010 ident: 1176_CR24 publication-title: Lancet doi: 10.1016/S0140-6736(10)60413-8 – volume: 46 start-page: 3095 issue: 17 year: 2010 ident: 1176_CR19 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2010.09.016 – volume: 77 start-page: 522 issue: 3 year: 2012 ident: 1176_CR4 publication-title: Lung Cancer doi: 10.1016/j.lungcan.2012.04.018 – volume: 36 start-page: 654 issue: 3 year: 2007 ident: 1176_CR21 publication-title: Int J Epidemiol doi: 10.1093/ije/dym020 – volume: 92 start-page: 71 year: 2003 ident: 1176_CR2 publication-title: BJU Int doi: 10.1111/j.1465-5101.2003.04402.x – volume: 10 start-page: 907 issue: 6 year: 2013 ident: 1176_CR23 publication-title: Clin Trials doi: 10.1177/1740774513498008 – volume: 122 start-page: 413 issue: 2 year: 2008 ident: 1176_CR10 publication-title: Int J Cancer doi: 10.1002/ijc.23126 – volume-title: Off National Statistics Statistical Bull year: 2012 ident: 1176_CR7 – volume: 163 start-page: 519 issue: 2 year: 2000 ident: 1176_CR8 publication-title: J Urol doi: 10.1016/S0022-5347(05)67915-3 – volume: 110 start-page: 2829 issue: 12 year: 2014 ident: 1176_CR17 publication-title: Br J Cancer doi: 10.1038/bjc.2014.242 – volume: 58 start-page: 1220 issue: 12 year: 2005 ident: 1176_CR20 publication-title: J Clin Epidemiol doi: 10.1016/j.jclinepi.2005.04.006 |
| SSID | ssj0017836 |
| Score | 2.1350348 |
| Snippet | Background
In cancer screening trials where the primary outcome is target cancer-specific mortality, the unbiased determination of underlying cause of death... In cancer screening trials where the primary outcome is target cancer-specific mortality, the unbiased determination of underlying cause of death (UCD) is... Background In cancer screening trials where the primary outcome is target cancer-specific mortality, the unbiased determination of underlying cause of death... |
| SourceID | pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 6 |
| SubjectTerms | Aged Cause of Death Cost-Benefit Analysis Data collection Diagnosis Early Detection of Cancer - economics Early Detection of Cancer - methods General Practitioners - statistics & numerical data Health aspects Health Sciences Humans Investigations Male Mass Screening - economics Mass Screening - methods Medical Records - standards Medical Records - statistics & numerical data Medicine Medicine & Public Health Middle Aged Patient outcomes Prostate cancer Prostate-Specific Antigen - blood Prostatic Neoplasms - diagnosis Prostatic Neoplasms - mortality Prostatic Neoplasms - prevention & control quality Reference Standards reporting Research Article Research Design Statistical Theory and Methods Statistics for Life Sciences Theory of Medicine/Bioethics United Kingdom |
| Title | Standardisation of information submitted to an endpoint committee for cause of death assignment in a cancer screening trial – lessons learnt from CAP (Cluster randomised triAl of PSA testing for Prostate cancer) |
| URI | https://link.springer.com/article/10.1186/1471-2288-15-6 https://www.ncbi.nlm.nih.gov/pubmed/25613468 https://www.proquest.com/docview/1681259165 https://pubmed.ncbi.nlm.nih.gov/PMC4429825 |
| Volume | 15 |
| WOSCitedRecordID | wos000349713200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: BioMedCentral customDbUrl: eissn: 1471-2288 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017836 issn: 1471-2288 databaseCode: RBZ dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1471-2288 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017836 issn: 1471-2288 databaseCode: DOA dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1471-2288 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017836 issn: 1471-2288 databaseCode: M~E dateStart: 20010101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1471-2288 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017836 issn: 1471-2288 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1471-2288 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017836 issn: 1471-2288 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1471-2288 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017836 issn: 1471-2288 databaseCode: PIMPY dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1471-2288 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017836 issn: 1471-2288 databaseCode: RSV dateStart: 20011201 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlR3LjtNAbLQPhPbCm6WwVEZCYjlEJJPMo8dS7Qoktoq2sCqn0SSZQKQqWbUpZ_6Bb-MH-BLsaVrRopXgEimyM3Zij-3J2B7GXkrpVJI5nEiZkkHiVBxkg8QGwhWZRZtpS18effVBjcd6Oh2keyxc18L4bPf1lqS31H5aa_kmQjMacI6CjUQg99khujpNU_FycrXZN6CahK4149_PbLmeXQP8hwfazY7c2SL1nuf87v_zfI_d6aJMGK7U4j7bc_UDdvui20d_yH5Ouj8IXTIPNCV0LVT97QJZq1oMRqFtwNbg6uK6qeoWkKwHOEBkyO1y4ejZggJJwDi8-uKzC3AwsAhGjZoDGiZcLCPb4I8IgV_ff8AMDSzqO_hDK1qgIhcYDVM4Hc2W1LoB0IUWDeogsTCvhjOikk6G0FJXEByKyKdUsYKxckfo9SP26fzs4-hd0B3wEOQiFm2QqZwPQnTTcVhwXahwUPJMhIlVMnJRyelgpZjnRSmsjYXMIptnnJcI46IUkYsfs4O6qd0TBkLxxGG0qG1SJhzVMo94oYWWsdM2LMoeC9ayN3nX_ZwO4ZgZvwrS0pCsDMnKRMLIHnu1wb9e9f24GZNUyZCUcESkvKprQL6otZYZCowT1ADXuj12soWJHzHfAr9YK6MhEGW_1a5ZLkxETeIEBvKix45XyrlhitMKMJG6x9SW2m4QqH_4NqSuvvo-4gnGIprjmKdr5TWdAVvc8K5P_x31GTvC2JISQwMen7CDdr50z9mt_FtbLeZ9tq-myl91nx2-PRunl33_OwTv0vcX6ee-n9e_ARfJSb0 |
| linkProvider | Springer Nature |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlR3LjtNAbLQsCLjwfgQWMBISu4eIZJKZJMeoYrWIblXRZbW30SSZQKQqWTUpZ_6Bb-MH-BLsaVKRopXgGNkZu7HH9nT8YOyNlCYKM4MbKYukG5oocLMk1K4wRabRZurSlkefT6PZLL64SOZ7zBtqYWy2-3AlaS213daxfOejGXU5R8H6wpXX2PUQvRUl8X1anG_vDagmoW_N-Pc7I9eza4D_8EC72ZE7V6TW8xzf_X-e77E7fZQJ6UYt7rM9Uz9gN0_7e_SH7Oei_wehT-aBpoS-hap9bJG1qsNgFLoGdA2mLi6bqu4AyVqAAUSGXK9bQ-8WFEgCxuHVF5tdgIuBRjBq1ArQMOFhGdkGOyIEfn3_AUs0sKjvYIdWdEBFLjBJ53A4Wa6pdQOgCy0a1EFiYVWlS6IyX6TQUVcQXIrIz6liBWPlntDRI_b5-P3Z5MTtBzy4uQhE52ZRzhMP3XTgFTwuIi8peSa8UEfSN37JabBSwPOiFFoHQma-zjPOS4RxUQrfBI_Zft3U5ikDEfHQYLQY67AMOapl7vMiFrEMTKy9onSYO8he5X33cxrCsVT2FBRLRbJSJCvlCyUd9naLf7np-3E1JqmSIinhikh5U9eAfFFrLZUKjBOiBM-6DjsYYeJHzEfg14MyKgJR9lttmnWrfGoSJzCQFw57slHOLVOcToChjB0WjdR2i0D9w8eQuvpq-4iHGIvEHNc8HJRX9QasveK3Pvt31Ffs1snZ6VRNP8w-Pme3Mc6kJFGXBwdsv1utzQt2I__WVe3qpd3BvwHsLUaR |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1fi9QwEA_nKYcv_v9TPXUEwfOhXJs2aQu-lNVF8VwKq8e9hbRNtbC0y7brs9_Bz-YX8JM4k3YXd-VA8HGZaTLdTCYzzcxvGHshpYnC3OBGyiPphiYK3DwJtStMmWu0mbqy5dHnZ9FsFl9cJNkBe72phbHZ7psryaGmgVCamv50WVbDFo_lqY8m1eUcF9kXrrzCrobUMIhi9fn59g6B6hNGmMa_n9k5hvaN8R-n0X6m5N51qT2Fpjf_T_5b7MbofUI6qMttdmCaO-zo43i_fpf9nI9fFsYkH2grGKFV7c8Oxax7dFKhb0E3YJpy2dZNDyiCJRhAZij0ujP0bEkOJqB_Xn-xWQc4GGgko6atAA0WBtH4CmBbh8Cv7z9ggYYX9wHYZhY9UPELTNIMTiaLNUE6AB6tZYu6SSKs6nRBs2TzFHpCC8GhaPqMKlnQhx4nenWPfZ6-_TR5546NH9xCBKJ386jgiYfHd-CVPC4jL6l4LrxQR9I3fsWp4VLAi7ISWgdC5r4ucs4rpHFRCd8E99lh0zbmIQMR8dCgFxnrsAo5qmvh8zIWsQxMrL2ycpi70QNVjKjo1JxjoWx0FEtFa6VorZQvlHTYyy3_csADuZyT1ErRKuGIOPNQ74ByEeSWSgX6D1GCMbDDjnc48U8sdsjPN4qpiERZcY1p153yCTxOoIMvHPZgUNStUJwiw1DGDot2VHjLQLjiu5Sm_mrxxUP0UWKOY55sFFmNhq275F0f_TvrM3aUvZmqs_ezD4_ZdXQ_KXfU5cExO-xXa_OEXSu-9XW3emo3828Z_U91 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Standardisation+of+information+submitted+to+an+endpoint+committee+for+cause+of+death+assignment+in+a+cancer+screening+trial+-+lessons+learnt+from+CAP&rft.jtitle=BMC+medical+research+methodology&rft.au=Williams%2C+Naomi+J&rft.au=Hill%2C+Elizabeth+M&rft.au=Ng%2C+Siaw+Yein&rft.au=Martin%2C+Richard+M&rft.date=2015-01-23&rft.pub=BioMed+Central+Ltd&rft.issn=1471-2288&rft.eissn=1471-2288&rft.volume=15&rft_id=info:doi/10.1186%2F1471-2288-15-6&rft.externalDocID=A541379026 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2288&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2288&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2288&client=summon |